The global single-cell analysis market size was valued at USD 2.2 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 15.0% from 2021 to 2028. An increase in investments and government funds deployed for research and development (R&D) in the field of medical diagnostics, availability of technically advanced products, and the rising adoption of single-cell analysis devices are some factors that can be attributed to the growth of the market.
Moreover, the advent of technology in single-cell amplification and manipulation techniques has led to the application of high throughput technologies in assays, thereby propelling revenue growth. In addition, the rapid development of microfluidic devices has significantly broadened the implementation of single-cell genomic/transcriptomic analysis in the biomedical field.
Technological advancements in sequencing techniques are transforming the landscape of single-cell omics research activities, including transcriptomic, epigenomics, and genomics. Significant advancements in sequencing reproducibility coupled with declining costs have helped process a large number of samples.
Increasing demand for analytical tools and technological advancements has led to the introduction of high-throughput machinery in the market. Several innovations have led to the introduction of new features such as high sensitivity, accuracy, and efficacy by utilizing scarce samples. Thus, key players are investing a significant amount in the development of solutions leading to a lucrative opportunity for revenue generation in the near future.
The ongoing pandemic of COVID-19 has triggered the adoption of single-cell analysis methods in virology research. The researchers are using these techniques to understand the immune profiles of infected patients. For instance, in a study published in January 2021, researchers from China performed high-dimensional single-cell analysis to understand the peripheral immune response to the COVID-19 infection.
Rapid technological advancements in single-cell techniques have enabled comprehensive analysis of the transcriptome and genome in an individual cell. These techniques help determine biological insights into single cells and offer solutions to explore relationships between cell events and host physiology. Expanding scope of applications of single-cell analysis in stem cell biology, tumor biology, developmental biology, immunology, and neurology, can aid in enhancing therapeutic decision-making with regards to precision medicine, and can positively affect the market growth.
Rising utility of single-cell analysis in disease diagnosis is expected to fuel the market growth over the forecast period. The technique has a significant impact on cancer diagnostics market as it allows detection and analysis of circulating tumor cells at a molecular level. It has also improved the understanding about the mechanisms underlying metastasis, invasion, and therapy resistance during cancer progression. This, in turn, has expanded the clinical use of single-cell analysis in areas such as early detection, guiding targeted therapy, and noninvasive monitoring.
Emerging sequencing technologies are revolutionizing single-cell omics research landscape across transcriptomics, genomics, and epigenomics applications, among others. Significant developments in sequencing reproducibility, alongside declining costs, have enabled large scale sample processing. Furthermore, research programs focused on single-nucleus RNA-sequencing suggest that the technique can offer sufficient resolution for sequencing different cell types, ranging from frozen specimens to post-mortem tissue samples. These factors are expected to boost the market growth in the near future.
Furthermore, development of various bioengineering approaches in the form of innovative microfluidic cell dissociation devices hold potential to radically transform dissociation of tissue specimens into individual cells. Demand for such devices is expected to rise due to their ability to prevent the inter-assay variation caused by human handling of tissue specimens. Similarly, applications of single-cell analysis in drug development are driven by development of various single-cell methods for studying drug responses in tumor populations. For instance, Beyondcell is a newly developed technology that utilizes single-cell RNA-sequencing data for identification of distinct drug responses in tumor cells.
PCR-based assays, stem cell therapies, and other single-cell analysis techniques typically involve high costs of instrumentation. In addition, other costs associated with installation, facilities, and maintenance add up to the entire system of single-cell analysis. Thus, high cost of the device is expected to impede the growth of the market in developing and lower-income countries.
Conventional methods of genomic study using DNA and RNA fragments can pose a threat to the market. Currently, majority of the workflows in genomic arena are based on conventional modes of gene studies. Presence of entities such as F. Hoffmann-La Roche Ltd and Illumina, Inc. that offer advanced sequencing products for genomics workflows based on DNA & RNA sample can hinder the market growth.
The consumables segment dominated the market and accounted for the largest revenue share of 57.1% in 2020 due to the high usability of products and frequent purchase of reagents, large-scale adoption of beads, and growing demand for assay kits. An increase in the prevalence of target diseases and the constant need for consumables required for the assays is propelling segment growth.
Moreover, reagents are consumables that are extensively used throughout cell analysis assays and hence the demand is always high. These reagents are available in different forms including multicolor cocktails, probes, markers, and phenotyping agents. As a result, the adoption and purchase of reagents lead to revenue generation in the market.
On the other hand, installation of new instruments and replacement of old instruments led to revenue generation for the instruments segment. Owing to the high-end features and the technically advanced analytical options, the automated instruments contributed to the substantial revenue in the market.
The cancer segment dominated the market and accounted for the largest revenue share of more than 30.0% in 2020. Single-cell analysis has proved to be effective for prior diagnostics of cancer cells, thus driving the segment. The mutation rates, proliferation conditions of cells, and cell types can be easily identified using these techniques.
The presence of a substantial number of research entities engaged in evaluating single-cell genomics and proteomics for the investigation of various therapeutic areas such as neuroscience, cancer, and infectious diseases has led to increasing adoption of single-cell analysis methods in diagnostics and therapeutic applications.
Increasing adoption of stem cell therapies is proving beneficial to the single-cell analysis market. The extensive application area of stem cell therapies is widening the scope of stem cell genomics, proteomics, and epigenetics. The therapies like regeneration of hair, bone marrow transplant, and organ transplants are boosting the adoption rates of single-cell analysis techniques.
The single-cell isolation and library preparation segment dominated the market and accounted for the largest revenue share of 25.8% in 2020. Given the wide range of single-cell applications, the demand for cell isolation and library preparation products (kits and reagents) is also high. In addition, a substantial number of companies are offering products in this segment, in turn, augmenting revenue growth.
On the other hand, owing to technological advancements such as the emergence of next-generation sequencing for analyzing cell expressions, the downstream analysis segment is gaining traction over the past few years. Also, the market is witnessing an increasing adoption of machine learning and artificial intelligence in data analysis.
Several computational methods have been developed and are being employed owing to their benefits such as scalability, flexibility, and high success rates. Thus, the high employment of such data analysis tools would spur market growth in the near future.
In 2020, the academic and research laboratories segment dominated the market and accounted for the largest revenue share of over 70.0%. Single-cell analysis technology is being widely employed in research settings. The substantial number of ongoing research projects at universities that employ single-cell analysis assays have led to increased adoption of various single-cell analyses at research settings.
The advent of spatial genomics that accelerates the single-cell analysis in research settings is another key factor driving the segment growth. Academic researchers are engaged in assessing spatial heterogeneity in gene expression profiles at a single cellular level. Furthermore, single-cell transcriptomics is found to be useful for neuroscientists to understand cell types forming the brain.
Technological advancements such as the use of microfluidics for the development of next-generation therapies have increased the adoption of single-cell analysis by biotechnology and pharmaceutical companies. Moreover, increasing penetration of genomic technologies in drug development would further drive the market. A substantial number of pharma firms have invested in genomics to have access to various genomics databases.
North America held the largest share accounting for 34.07% of the market value in 2021. This can be attributed to various factors such as increasing personal healthcare expenditure, rise in government funding opportunities, rapid adoption of novel analytical techniques, growing scientific awareness about single-cell techniques and availability of skilled personnel in the region.
The U.S. held the largest market share within North America single-cell analysis market in 2021. Its lead is mainly attributed to availability of a highly developed healthcare infrastructure, increasing focus on personalized medicine, and rise in government initiatives and private funding, among other factors. Over the past few decades, the National Institutes of Health has taken various initiatives to increase awareness regarding the importance of early diagnosis, and to drive the adoption of noninvasive diagnostics. Furthermore, the growing adoption of advanced therapeutic techniques in the U.S. healthcare sector is another factor boosting the market.
In Germany, reimbursements for single-cell analysis technologies are only offered for therapies approved by the German Diagnosis-related Group. Thus, adoption of single-cell analysis technologies is limited in the country. On the other hand, schemes such as “Statutory Health Insurance” consolidate healthcare infrastructure, enabling patients to undergo advanced treatment. The German government has adopted regulatory guidelines set by European Commission for approval of diagnostic instruments for commercialization. Hence, the presence of clear and well-structured regulatory framework can help support the introduction of advanced single-cell analysis products in German market.
The key companies have focused on the development of innovative and technologically advanced products to fulfill consumer demands. For instance, in February 2021, SeqWell Inc. launched plexWell Single Cell Rapid Kit for single-cell RNA sequencing. It is used for the simplified preparation of NGS libraries. Furthermore, the company has signed a distribution agreement with CELLINK AB in February 2021 for the commercialization of its products to expand its presence outside the U.S. Such company initiatives are expected to intensify market competition.
This market space is continuously growing for the past few years owing to the increasing uptake of these techniques for diagnostic applications. The growing prevalence of genetic disorders has resulted in an increasing need for early diagnosis. This has created lucrative opportunities for emerging players to capture untapped avenues of the market. Some of the prominent players in the single-cell analysis market include:
Thermo Fisher Scientific Inc.
QIAGEN NV
Bio-Rad Laboratories Inc.
Illumina Inc.
Merck Millipore
Becton
Dickinson & Company
Fluidigm Corporation
10x Genomics, Inc.
BGI
Novogene Corporation
Report Attribute |
Details |
Market size value in 2021 |
USD 2.4 billion |
Revenue forecast in 2028 |
USD 6.7 billion |
Growth Rate |
CAGR of 15.0% from 2021 to 2028 |
Base year for estimation |
2020 |
Historical data |
2017 - 2019 |
Forecast period |
2021 - 2028 |
Quantitative units |
Revenue in USD Million and CAGR from 2021 to 2028 |
Report coverage |
Revenue forecast, company share, competitive landscape, growth factors, and trends |
Segment coverage |
Product type, application, workflow, end-use, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; France; Italy; Spain; China; India; Japan; South Korea; Brazil; Mexico; South Africa; Saudi Arabia |
Companies profiled |
Thermo Fisher Scientific Inc.; QIAGEN NV; Bio-Rad Laboratories Inc.; Illumina Inc.; Merck Millipore; Becton; Dickinson & Company; Fluidigm Corporation; 10x Genomics, Inc.; BGI; Novogene Corporation |
Customization scope |
If you need specific market information, which is not currently within the scope of the report, we will provide it to you as a part of the customization |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2028. For the purpose of this study, Grand View Research has segmented the global single-cell analysis market report on the basis of product, application, workflow, end-use, and region:
Product Outlook (Revenue, USD Million, 2017 - 2028)
Consumables
Reagents
Assay Kits
Instruments
Microscope
Hemocytometers
Flow Cytometers
NGS Systems
PCR
High Content Screening Systems
Cell Microarrays
Single Live Cell Imaging
Automated Cell Counters
Application Outlook (Revenue, USD Million, 2017 - 2028)
Cancer
Immunology
Neurology
Stem cell
Non-invasive prenatal diagnosis
In-vitro fertilization
Others
Workflow Outlook (Revenue, USD Million, 2017 - 2028)
Single Cell Isolation & Library Preparation
Downstream Analysis
Data Analysis
End-use Outlook (Revenue, USD Million, 2017 - 2028)
Academic & Research Laboratories
Biotechnology and Pharmaceutical Companies
Hospitals and Diagnostic Laboratories
Others
Regional Outlook (Revenue, USD Million, 2017 - 2028)
North America
U.S.
Canada
Europe
Germany
U.K.
France
Italy
Spain
Asia Pacific
China
India
Japan
South Korea
Latin America
Mexico
Brazil
MEA
South Africa
Saudi Arabia
b. The global single-cell analysis market size was estimated at USD 2.2 billion in 2020 and is expected to reach USD 2.4 billion in 2021.
b. The global single-cell analysis market is expected to grow at a compound annual growth rate of 15% from 2021 to 2028 to reach USD 6.7 billion by 2028.
b. Consumables dominated the single-cell analysis market with a share of 57.1% in 2020. This is attributable to the high penetration of reagents & kits in the market coupled with their high usage and purchase rate.
b. Some key players operating in the single-cell analysis market include Illumina, Inc.; Thermo Fisher Scientific, Inc.; Qiagen N.V.; Bio-Rad Laboratories, Inc.; Merck Millipore GmbH; Fluidigm, 10x Genomics, Inc.; BGI; and Novogene Corporation.
b. Key factors that are driving the market growth include increasing implementation of single-cell assessment within the diagnostics and pharmaceutical manufacturing industry, and declining prices of sequencing technology that accelerate single-cell genome sequencing.
b. The cancer segment dominated the global single-cell analysis market and accounted for the largest revenue share of more than 30.0% in 2020.
b. The single-cell isolation and library preparation segment dominated the global single-cell analysis market and accounted for the largest revenue share of 25.8% in 2020.
b. The academic and research laboratories segment dominated the global single-cell analysis market and accounted for the largest revenue share of over 70.0%.
b. North America dominated the global single-cell analysis market and accounted for the largest revenue share of 35.0% in 2020.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure.
"The quality of research they have done for us has been excellent."
Biopharmaceutical innovators are at the forefront of the human response to the coronavirus pandemic. A significant number of major biotech firms are in the midst of a race to investigate the Sars-Cov-2 genome and prepare a viable vaccine for the same. As compared to the speed of response to SARS/MERs etc, the biotech entities are investigating SARs-Cov-2 at an unprecedented rate and a considerable amount of funds are being put into the R&D. With multiple candidates in trial, the public and private sectors are anticipated to work in unison for the foreseeable period, until a vaccine is developed for Covid-19. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.